PT1347760E - Composicoes farmaceuticas de agonista do receptor de nmda - Google Patents

Composicoes farmaceuticas de agonista do receptor de nmda

Info

Publication number
PT1347760E
PT1347760E PT01270205T PT01270205T PT1347760E PT 1347760 E PT1347760 E PT 1347760E PT 01270205 T PT01270205 T PT 01270205T PT 01270205 T PT01270205 T PT 01270205T PT 1347760 E PT1347760 E PT 1347760E
Authority
PT
Portugal
Prior art keywords
receptor agonist
nmda receptor
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
PT01270205T
Other languages
English (en)
Inventor
Yesook Kim
Jinyang Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT1347760E publication Critical patent/PT1347760E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01270205T 2000-12-13 2001-12-05 Composicoes farmaceuticas de agonista do receptor de nmda PT1347760E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13

Publications (1)

Publication Number Publication Date
PT1347760E true PT1347760E (pt) 2005-09-30

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01270205T PT1347760E (pt) 2000-12-13 2001-12-05 Composicoes farmaceuticas de agonista do receptor de nmda

Country Status (42)

Country Link
US (2) US6635270B2 (pt)
EP (1) EP1347760B1 (pt)
JP (1) JP2004515529A (pt)
KR (1) KR100533407B1 (pt)
CN (1) CN1273135C (pt)
AP (1) AP1235A (pt)
AR (1) AR035607A1 (pt)
AT (1) ATE296629T1 (pt)
AU (2) AU2002218454B2 (pt)
BG (1) BG107788A (pt)
BR (1) BR0116085A (pt)
CA (1) CA2431172A1 (pt)
CZ (1) CZ20031543A3 (pt)
DE (1) DE60111265T2 (pt)
DO (1) DOP2001000300A (pt)
DZ (1) DZ3484A1 (pt)
EA (1) EA006489B1 (pt)
EC (1) ECSP034655A (pt)
EE (1) EE200300284A (pt)
ES (1) ES2239648T3 (pt)
GE (1) GEP20053568B (pt)
HK (1) HK1059575A1 (pt)
HR (1) HRP20030473A2 (pt)
HU (1) HUP0400645A2 (pt)
IL (1) IL155810A0 (pt)
IS (1) IS6811A (pt)
MA (1) MA26970A1 (pt)
MX (1) MXPA03005257A (pt)
NO (1) NO20032678D0 (pt)
NZ (1) NZ525742A (pt)
OA (1) OA12414A (pt)
PA (1) PA8534901A1 (pt)
PE (1) PE20020710A1 (pt)
PL (1) PL362080A1 (pt)
PT (1) PT1347760E (pt)
SK (1) SK6982003A3 (pt)
TN (1) TNSN01173A1 (pt)
UA (1) UA73619C2 (pt)
UY (1) UY27068A1 (pt)
WO (1) WO2002047685A2 (pt)
YU (1) YU41103A (pt)
ZA (1) ZA200303892B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2368553E (pt) 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
CL2008000119A1 (es) * 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EP2542254B1 (en) 2010-02-11 2018-09-26 Northwestern University Nmda receptor agonists and uses thereof
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
JP2016506961A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
AU2014212484B2 (en) 2013-01-29 2018-01-04 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA receptor modulators and uses thereof
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
BR112015018094A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR20150073866A (ko) 2013-12-23 2015-07-01 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
EA201892657A1 (ru) 2016-05-19 2019-05-31 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2019001321A (es) 2016-08-01 2019-07-04 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
BR112019001923A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores de nmda de espiro-lactama e métodos de sua utilização
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
IL122649A (en) * 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
MXPA03005257A (es) 2003-09-25
AR035607A1 (es) 2004-06-16
AU2002218454B2 (en) 2005-10-27
EE200300284A (et) 2003-10-15
NO20032678L (no) 2003-06-12
SK6982003A3 (en) 2004-08-03
JP2004515529A (ja) 2004-05-27
TNSN01173A1 (fr) 2005-11-10
DE60111265D1 (de) 2005-07-07
YU41103A (sh) 2006-05-25
KR100533407B1 (ko) 2005-12-02
EP1347760A2 (en) 2003-10-01
EA006489B1 (ru) 2005-12-29
WO2002047685A2 (en) 2002-06-20
ES2239648T3 (es) 2005-10-01
NZ525742A (en) 2005-07-29
ZA200303892B (en) 2004-05-20
IL155810A0 (en) 2003-12-23
CZ20031543A3 (cs) 2004-06-16
GEP20053568B (en) 2005-07-11
CN1479617A (zh) 2004-03-03
HUP0400645A2 (hu) 2004-06-28
CN1273135C (zh) 2006-09-06
NO20032678D0 (no) 2003-06-12
PL362080A1 (en) 2004-10-18
PA8534901A1 (es) 2002-08-26
US6635270B2 (en) 2003-10-21
AP2001002376A0 (en) 2001-12-31
ATE296629T1 (de) 2005-06-15
US20020111366A1 (en) 2002-08-15
BR0116085A (pt) 2003-12-23
US20040039022A1 (en) 2004-02-26
BG107788A (bg) 2004-01-30
MA26970A1 (fr) 2004-12-20
DOP2001000300A (es) 2002-05-30
HRP20030473A2 (en) 2005-04-30
EA200300514A1 (ru) 2003-10-30
HK1059575A1 (en) 2004-07-09
UY27068A1 (es) 2002-07-31
OA12414A (en) 2006-04-18
AP1235A (en) 2004-01-06
CA2431172A1 (en) 2002-06-20
UA73619C2 (en) 2005-08-15
DE60111265T2 (de) 2006-05-04
ECSP034655A (es) 2003-07-25
IS6811A (is) 2003-05-08
AU1845402A (en) 2002-06-24
PE20020710A1 (es) 2002-08-09
DZ3484A1 (fr) 2002-06-20
KR20030070060A (ko) 2003-08-27
WO2002047685A3 (en) 2002-08-15
EP1347760B1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
PT1347760E (pt) Composicoes farmaceuticas de agonista do receptor de nmda
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
DE60138706D1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
NO20030418L (no) Nytt farmasöytisk preparat
DE60132799D1 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
DE60122495D1 (de) TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
ATE291900T1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
MA26890A1 (fr) Metabolites agonistes/ antagonistes d'oestrogenes
NO20013978L (no) Dopamin D1 reseptor agonist forbindelser
DK1347760T3 (da) Farmaceutiske kompositioner med NMDA receptor agonister
GB0130576D0 (en) Dopamine D1 receptor agonist pro-drug compounds & derivatives
SE0003996D0 (sv) Receptorantagonister
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
UA4167S (uk) Набір упаковок для ліків «метрозол»
LT2000015A (lt) Nesteroidiniai ligandai estrogeno receptoriui
GB0020710D0 (en) Dopamine D1 receptor agonist pro-drug compounds & derivatives